Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
Clinical Trials
4
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2013
Active, not recruiting
1
25.0%
Completed
1
25.0%
Recruiting
2
50.0%
No approval data available
- Johnson & Johnson has agreed to acquire Firefly Bio for $1 billion in an all-cash deal, gaining access to its proprietary Firelink degrader-antibody conjugate (DAC) platform. - The Firelink platform is designed to deliver highly selective protein degraders to KRAS-driven tumor cells while sparing healthy tissue, addressing a notoriously undruggable target. - KRAS mutations occur in nearly a quarter of all human cancers, and patients with KRAS-driven cancers currently face limited treatment options with survival measured in months. - The acquisition, expected to close before the end of 2026 pending regulatory approvals, diversifies J&J's oncology pipeline with preclinical candidates for multiple solid tumor types.
- The FDA has approved VEPPANU (vepdegestrant), marking the first-ever approval of a PROTAC protein degrader therapy for treating ESR1-mutated, ER+/HER2- advanced breast cancer. - The approval was based on VERITAC-2 Phase 3 trial results showing a 43% reduction in disease progression risk compared to fulvestrant, with median progression-free survival of 5 months versus 2.1 months. - VEPPANU addresses a significant unmet medical need for patients with endocrine-resistant breast cancer, where up to 40-50% develop ESR1 mutations after CDK4/6 inhibitor treatment. - Arvinas and Pfizer jointly developed the drug and plan to select a third-party partner for commercialization to maximize its therapeutic potential.
- Ternary Therapeutics raised £3.6 million in seed funding to scale its AI-powered platform for designing molecular glue drugs that force proteins to bind together for therapeutic purposes. - The London-based company combines physics-informed AI, molecular dynamics modeling, and laboratory testing to systematically design molecular glues rather than relying on accidental discovery. - The platform has already generated a preclinical pipeline targeting inflammatory diseases and secured multiple research collaborations with pharmaceutical and biotechnology companies. - Former Arvinas R&D president Dr. Ian Taylor joined Ternary's board, bringing expertise from targeted protein degradation research and six IND submissions during his tenure.
- Northwestern University researchers developed HYDRACs, protein-like polymers that induce proximity-based degradation of notoriously undruggable cancer proteins Myc and KRAS. - Unlike traditional PROTACs or molecular glues, HYDRACs use peptide-decorated polymer chains that grab target proteins like "fingers on a hand" and recruit cellular degradation machinery. - The approach addresses the challenge of intrinsically disordered proteins like Myc, which lack defined binding pockets for small-molecule drugs. - The study, published in Nature Communications, represents a novel modality in the rapidly expanding proximity medicine field, distinct from PROTACs, molecular glues, and RIPTACs.
- Arvinas has appointed Randy Teel, Ph.D., as President and CEO, succeeding John Houston who is retiring after nine years of leadership. - The leadership transition comes after Arvinas achieved its first-ever successful pivotal trial of a PROTAC degrader, marking a significant milestone for the protein degradation platform. - The company is advancing multiple clinical programs including ARV-102 for neurodegenerative disorders, ARV-393 for non-Hodgkin lymphoma, and ARV-806 for KRAS G12D mutated cancers. - Under Houston's leadership, Arvinas raised over $2 billion in funding and established itself as the industry leader in targeted protein degradation therapeutics.
- Carrick Therapeutics announced positive Phase 2 results for samuraciclib combined with fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer patients previously treated with CDK4/6 inhibitors. - The combination achieved a 55% overall response rate and 14.5-month median progression-free survival in patients without TP53 mutations, compared to 29% and 6.8 months with fulvestrant alone. - Samuraciclib represents a first-in-class oral CDK7 inhibitor that could provide a new treatment option for the 70% of second-line patients who are TP53 wild-type. - The company plans to advance samuraciclib into Phase 3 trials in 2026 based on these encouraging efficacy and safety results.
- Arvinas presented preclinical data at ASH 2025 showing that the combination of ARV-393 and glofitamab achieved up to 91% tumor growth inhibition in B-cell lymphoma models, significantly outperforming either agent alone. - The combination demonstrated complete tumor regression in all mice at higher doses, with mechanistic studies revealing that ARV-393 upregulates CD20 expression and enhances immune signaling pathways. - Based on these results, Arvinas plans to initiate a Phase 1 combination clinical trial in diffuse large B-cell lymphoma patients in 2026, pursuing a chemotherapy-free treatment approach. - ARV-393 is an oral PROTAC protein degrader targeting BCL6, a historically undruggable protein that drives B-cell lymphoma survival and proliferation.
- Over 250 companies are developing more than 300 pipeline drugs for breast cancer treatment, representing a vibrant R&D landscape with significant therapeutic opportunities. - Emerging therapies include innovative approaches such as PROTACs, antibody-drug conjugates (ADCs), and CDK inhibitors specifically targeting resistant breast cancer cases. - Key pipeline drugs include Vepdegestrant (ARV-471) with FDA Fast Track designation, Utidelone approved in China, and ARX788 anti-HER2 ADC in clinical trials. - The pipeline encompasses drugs at various development stages from preclinical to registration, with focus on novel therapies for resistant cases and targeted small molecules.
- Targeted protein degradation (TPD) has evolved from niche science to mainstream drug development, with over 40 PROTAC candidates in clinical testing and the first potential market approval expected for Arvinas/Pfizer's ARV-471 by June 2026. - Major pharmaceutical companies have committed over $10 billion in partnerships since 2024, with deals including AbbVie's $1.64 billion agreement with Neomorph and LEO Pharma's $1.7 billion alliance with Gilead Sciences. - The Asia-Pacific region, particularly China and South Korea, has emerged as a leading hub for TPD research, with multiple companies advancing candidates through late-stage clinical trials. - The global TPD market is projected to surge from $1 billion currently to $6.94 billion by 2035, driven by advances in computational tools and AI-enabled drug design.
- John Houston, Ph.D., CEO and President of Arvinas, announces plans to retire from executive roles after eight years of leadership, while remaining as Board Chairperson. - Under Houston's leadership, Arvinas achieved multiple industry firsts for PROTAC protein degraders, including the first positive pivotal Phase 3 trial and first new drug application. - The company has advanced six PROTAC programs into clinical trials and demonstrated for the first time that orally administered PROTACs can achieve pharmacodynamic activity in the central nervous system. - Arvinas Board of Directors has initiated a search for Houston's successor to continue advancing the company's targeted protein degradation platform across multiple therapeutic areas.
